Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF).

American Heart Journal
James L JanuzziScott D Solomon

Abstract

Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor indicated for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; however, its mechanism of benefit remains unclear. Biomarkers that are linked to ventricular remodeling, myocardial injury, and fibrosis may provide mechanistic insight and important clinical guidance regarding sacubitril/valsartan use. This 52-week, multicenter, open-label, single-arm study is designed to (1) correlate biomarker changes with cardiac remodeling parameters, cardiovascular outcomes, and patient-reported outcome data and (2) determine short- and long-term changes in concentrations of biomarkers related to potential mechanisms of action and effects of sacubitril/valsartan therapy. Approximately 830 patients with HF with reduced ejection fraction will be initiated and titrated on sacubitril/valsartan according to United States prescribing information. Primary efficacy end points include the changes in N-terminal pro-B-type natriuretic peptide concentrations and cardiac remodeling from baseline to 1 year. Secondary end points include changes in concentrations of N-terminal pro-B-type natriuretic peptide and remodeling to 6 months, and changes in p...Continue Reading

References

Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
Mar 10, 2001·Clinical Pharmacology and Therapeutics·UNKNOWN Biomarkers Definitions Working Group.
Mar 17, 2010·Pacing and Clinical Electrophysiology : PACE·Maria-Aurora MoralesSilvia Del Ry
Nov 13, 2010·European Journal of Cardiovascular Nursing : Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology·Seongkum HeoTerry A Lennie
Jan 15, 2011·JACC. Cardiovascular Imaging·Marvin A KonstamJames E Udelson
Mar 30, 2011·Journal of the National Medical Association·Judith E MitchellJackson T Wright
Jan 10, 2012·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Clinton D Kemp, John V Conte
Apr 5, 2012·Journal of Cardiovascular Medicine·Andrew P AmbrosyMihai Gheorghiade
Jul 19, 2012·Circulation·Loek van HeerebeekWalter J Paulus
Dec 28, 2012·European Journal of Internal Medicine·Märit MejhertThomas Kahan
Nov 10, 2013·Journal of the American Heart Association·Vanessa XanthakisRamachandran S Vasan
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Dec 3, 2014·Journal of Cardiac Failure·Antoni Bayes-GenisJosep Lupón
Mar 15, 2015·Journal of the American College of Cardiology·Eugene Braunwald
Mar 18, 2015·Journal of Cardiovascular Translational Research·Shweta R MotiwalaJames L Januzzi
Jan 13, 2016·Circulation. Heart Failure·Michael R ZileUNKNOWN Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction (PARAMOUNT) Investig
Mar 5, 2016·Nature Reviews. Cardiology·Boback Ziaeian, Gregg C Fonarow
Apr 28, 2017·Circulation·Sheryl L ChowUNKNOWN American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovas

❮ Previous
Next ❯

Citations

Mar 6, 2019·European Journal of Heart Failure·Naveen L PereiraAllan S Jaffe
Jul 11, 2019·Journal of Comparative Effectiveness Research·Herminio Morillas-ClimentAlfonso Valle-Muñoz
Aug 1, 2019·Clinical Chemistry·Antoni Bayes-Genis, Julio Núñez
Oct 26, 2018·Circulation Research·Nasrien E Ibrahim, James L Januzzi
Jun 22, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Antonis S ManolisHelen Melita
Aug 18, 2020·Therapeutics and Clinical Risk Management·Sara AkbarWilbert S Aronow
Aug 11, 2019·International Journal of Molecular Sciences·Maurizio ForteSebastiano Sciarretta
Sep 19, 2020·European Journal of Heart Failure·Nasrien E IbrahimUNKNOWN Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (P
Oct 6, 2020·Circulation. Heart Failure·Nasrien E IbrahimUNKNOWN Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (P
Nov 16, 2020·JACC. Heart Failure·D H Frank GommansRoland R J van Kimmenade
May 1, 2021·JACC. Heart Failure·D H Frank GommansRoland R J van Kimmenade
Sep 24, 2021·European Journal of Clinical Pharmacology·Egle CorradoCesare de Gregorio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.